Navigation Links
Pharmaxis to Expand Manufacturing Capacity
Date:11/2/2007

SYDNEY, Australia, Nov. 2 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced moves to expand its manufacturing capacity with the signing of an agreement for the construction of a new state of the art facility at Frenchs Forest, Sydney.

Following completion of construction in the fourth quarter of 2008, Pharmaxis may lease the 7,000 square metre manufacturing and research facility for a term of 15 years with two options to renew of five years each.

The purpose built facility will include an expanded manufacturing plant with initial capacity sufficient to supply Bronchitol to approximately 40,000 patients per year. Pharmaxis is developing Bronchitol for the treatment of diseases including cystic fibrosis, bronchiectasis and chronic bronchitis.

Construction of the key manufacturing equipment commenced in Denmark earlier in the year. In addition to manufacturing, the facility will house the commercial, clinical and administration functions of the company as well as the drug discovery group which is currently located at North Ryde.

The premises will provide further opportunities to expand initial capacity in a modular fashion.

About Pharmaxis

Pharmaxis (ACN 082 811 630) is a pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and immune disorders. Its development pipeline of products include: Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD) and PXS64 for the treatment of multiple sclerosis.

Founded in 1998, Pharmaxis is listed on the Australian Stock Exchange (symbol PXS), and on NASDAQ Global Market (symbol PXSL). The company is headquartered in Sydney at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to http://www.pharmaxis.com.au or contact Jane Sugden, Investor Relations +61 2 9454 7230.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

CONTACT:

Alan Robertson - Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

RELEASED THROUGH:

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgroup.com

Australia:

Felicity Moffatt

Tel: +61-418-677-701

Email: moffattf@healthpr.com


'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Expandable metal stents used in digestive cancers
2. Obesity And Expanding Waistlines the next Epidemic in USA
3. Art of Living concept expanding around the globe
4. Colorblind Individuals have expanded color vision
5. The Cleveland Clinic Expands Its Services across the World via the Net
6. Ranbaxy Expands By Acquiring A Generic Company In Belgium
7. Insulin and Growth Hormone, Expands Life Span?
8. ISRO To Expand Telemedicine Network, 4 Speciality Hospitals To Be Included
9. Codex role likely to expand
10. Expanded Infant Health Screening
11. Expanding Price Control Detrimental for Pharma Companies: CII
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. ... announced a development collaboration with the Australian critical medicine company, Phebra Pty ... schizophrenia. , LAI medicines can offer improved therapeutic benefits over oral formulations, including ...
(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is ... to cover the latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, ... the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic ...
(Date:5/5/2016)... ... May 05, 2016 , ... This weekend, from Friday, May 6 - Sunday, May ... California terrain at the first Team Semper Fi Mountain Bike Camp, hosted in conjunction with ... mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with the injured ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... exercises, the Wharton Seminars for Business Journalists , led by the ... key business and economic issues.  This one-day program at the Wharton School’s ...
(Date:5/5/2016)... ... ... Derrin Doty Group has unveiled the latest charity campaign in their ongoing community ... The insurance provider’s caring team has been so moved by the sudden death of ... the flu, that they have decided to extend their original campaign. Compassionate community members ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and Markets has announced ... in the USA"  report to their offering.  ,     (Logo: ... the current Positron Emission Tomography (PET) scanner and cyclotron ... market. Along with the current known number of PET ... , the report also contains a detailed breakdown of ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocytopenia Market and ... to their offering.       ... ,The latest research Europe Thrombocytopenia Market ... provides comprehensive insights into Thrombocytopenia pipeline ...
(Date:5/4/2016)... Conn., May 4, 2016  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... ended March 31, 2016. First Quarter 2016 ... and Reinvestment ("CAD" or "Cash Flow") of $13.6 million ... net loss of $15.0 million for the first quarter ...
Breaking Medicine Technology: